Interleukin 1 receptor antagonist (IL1RA) in acute leukaemia: IL1RA is both secreted spontaneously by myelogenous leukaemia blasts and is a part of the acute phase reaction in patients with chemotherapy‐ induced leucopenia

Abstract

Blast cells derived from peripheral blood of patients with acute myelogenous leukaemia (AML) were cultured in vitro and interleukin 1 receptor antagonist (IL1RA) concentrations determined in culture supernatants. AML blasts derived from patients classified as AML‐M4 and AML‐M5 subtype showed an increased release of IL1RA. IL1α and IL1β caused a similar increase in AML blast release of IL1RA, and addition of anti‐ILl antibodies decreased IL1RA release. IL1RA release from AML blasts was also increased by stem cell factor, tumour necrosis factor α (TNFα), granulocyte‐macrophage colony‐stimulating factor and macrophage colony‐stimulating factor, whereas interleukin 3, interleukin 6, leukaemia inhibitory factor and granulocyte colony‐ stimulating factor did not significantly alter IL1RA release. When investigating IL1RA serum levels, serum concentrations were decreased in acute leukaemia patients with chemotherapy‐induced cytopenia compared with healthy controls. Serum levels of both IL1RA as well as IL1β and soluble TNFα receptors increased when the leucopenic patients developed complicating bacterial infections.

Identification of a subset of patients with acute myeloid leukemia characterized by long-termin vitroproliferation and altered cell cycle regulation of the leukemic cells

“…IL-1RA is secreted spontaneously by AML cells [67] and its major function is to competitively inhibit receptor binding of IL-1 that has been shown to play a role in AML proliferation. Addition of IL-1RA to cell cultures has been shown to decrease AML colony formation [68], but the concentrations used in this study were much higher than those concentrations found in our long-term cultures.…”

Disease‐stabilizing treatment with all‐trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti‐leukemic treatment

“…The cytokine-cluster analysis showed several alterations during treatment, an observation suggesting this treatment alters the cytokine network. Several of the cytokines included in the present analyses have effects on primary human AML cells [30,[42][43][44][45], and the altered cytokine network may thereby directly affect the AML cells and also have immunomodulatory effects.…”

Serum Interleukin-6 and CCL11/Eotaxin May Be Suitable Biomarkers for the Diagnosis of Chronic Nonbacterial Osteomyelitis

“…Here, IL-1RA levels were increased in sera from CRMO patients when compared to healthy controls, indirectly indicating increased inflammasome activation and IL-1β release. The post-translational regulator IL-1RA, however, directly reflects IL-1β release and may therefore be used as an indirect marker for IL-1β secretion ( 13 ). In a previous study ( 10 ), serum IL-1RA was not different between CRMO patients, JIA patients and healthy individuals.…”